Louisiana State Employees Retirement System Buys Shares of 16,100 TransMedics Group, Inc. (NASDAQ:TMDX)

Louisiana State Employees Retirement System bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 3rd quarter, HoldingsChannel reports. The fund bought 16,100 shares of the company’s stock, valued at approximately $2,528,000.

Several other institutional investors have also recently added to or reduced their stakes in TMDX. Wasatch Advisors LP bought a new stake in TransMedics Group during the first quarter valued at $32,162,000. Vaughan Nelson Investment Management L.P. bought a new stake in TransMedics Group during the second quarter valued at $39,862,000. Driehaus Capital Management LLC increased its stake in TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after purchasing an additional 202,867 shares during the last quarter. Hood River Capital Management LLC bought a new stake in TransMedics Group during the second quarter valued at $18,854,000. Finally, Canada Pension Plan Investment Board bought a new stake in TransMedics Group during the second quarter valued at $16,086,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

TMDX stock opened at $126.24 on Tuesday. The company has a market capitalization of $4.21 billion, a P/E ratio of 3,156.00 and a beta of 1.99. The company has a 50-day simple moving average of $147.58 and a 200 day simple moving average of $140.19. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company’s quarterly revenue was up 117.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.03) earnings per share. Sell-side analysts predict that TransMedics Group, Inc. will post 1.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TMDX has been the subject of several recent research reports. Robert W. Baird assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 24th. They set an “outperform” rating and a $200.00 target price for the company. Piper Sandler reissued an “overweight” rating and set a $180.00 price target on shares of TransMedics Group in a report on Monday, October 7th. Morgan Stanley boosted their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, Stephens boosted their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $174.30.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total value of $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares of the company’s stock, valued at approximately $1,353,514.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total value of $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares of the company’s stock, valued at approximately $1,353,514.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,267,557.11. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 64,205 shares of company stock valued at $9,981,907. 7.00% of the stock is owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.